Access to surgery in early-stage patients with non-small cell lung cancer is dependent upon the extent of racial segregation in the patient’s neighborhood, according to a new study in Cancer Epidemiology, Biomarkers & Prevention.
Access to surgery in early-stage patients with non-small cell lung cancer (NSCLC) is dependent upon the extent of racial segregation in the patient’s neighborhood, according to a new study in Cancer Epidemiology, Biomarkers & Prevention. This in turn influences patient outcomes.
A retrospective, cohort study among more than 8000 NSCLC patients in Georgia, using data from the Georgia Comprehensive Cancer Registry, evaluated the effect pf segregation, low income, and the combination, on the odds of surgical intervention in those patients.
The authors write that living in areas with the highest [absolute odds ratio (AOR), = 0.35, 95% CI, 0.19-0.64] and second highest (AOR = 0.37, 95% CI, 0.20-0.68) levels of segregation was associated with decreased odds of receipt of surgery. This in turn had a significant impact on patient survival, with black patients in the segregated regions being 31% more likely to die of the disease. The inverse correlation held true in white patients in the low-income neighborhoods, but only with respect to their access to surgery—not survival.
“Our findings suggest how black and white individuals experience segregation and area-level poverty is likely different leading to differences in adverse health outcomes,” the authors conclude.
“At least half of patients diagnosed at early stages who undergo surgical treatment survive more than five years, whereas, without surgery, most will die within a year,” said the study’s lead author Asal Mohamadi Johnson, PhD, MPH, in a statement. “Health disparities are a result of a combination of social, cultural, behavioral, and political factors. Any genuine commitment to address them successfully should include experts on economic development and urban planning, as well as policymakers and the medical community,” Johnson continued. “Most importantly, the residents of these communities must be involved and a part of the process.”
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More